Immunocore (NASDAQ:IMCR) Shares Down 4.2%

Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) traded down 4.2% during trading on Tuesday . The stock traded as low as $57.84 and last traded at $57.97. 392,620 shares were traded during mid-day trading, a decline of 18% from the average session volume of 480,380 shares. The stock had previously closed at $60.50.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Mizuho upped their price objective on shares of Immunocore from $86.00 to $90.00 and gave the stock a "buy" rating in a report on Tuesday, March 5th. HC Wainwright restated a "buy" rating and issued a $90.00 price objective on shares of Immunocore in a report on Wednesday, March 6th. JPMorgan Chase & Co. upped their price objective on shares of Immunocore from $60.00 to $70.00 and gave the stock an "overweight" rating in a report on Wednesday, March 20th. Oppenheimer restated an "outperform" rating and issued a $87.00 price objective (up from $85.00) on shares of Immunocore in a report on Thursday, February 29th. Finally, Canaccord Genuity Group upped their price objective on shares of Immunocore from $60.00 to $63.00 and gave the stock a "hold" rating in a report on Thursday, February 29th. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. Based on data from MarketBeat, Immunocore currently has an average rating of "Moderate Buy" and an average target price of $80.55.

Immunocore Stock Performance

The firm has a market capitalization of $2.89 billion, a P/E ratio of -50.01 and a beta of 0.89. The company has a current ratio of 3.80, a quick ratio of 3.77 and a debt-to-equity ratio of 0.13. The business's 50 day simple moving average is $66.88 and its two-hundred day simple moving average is $60.08.

Immunocore (NASDAQ:IMCR - Get Free Report) last released its quarterly earnings data on Wednesday, February 28th. The company reported ($0.40) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.12). The firm had revenue of $70.16 million for the quarter, compared to the consensus estimate of $53.25 million. Immunocore had a negative net margin of 22.48% and a negative return on equity of 15.78%. The firm's revenue for the quarter was up 22.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.63) earnings per share. Sell-side analysts anticipate that Immunocore Holdings plc will post -1.54 EPS for the current fiscal year.

Institutional Trading of Immunocore

A number of institutional investors have recently made changes to their positions in the stock. Fred Alger Management LLC boosted its holdings in shares of Immunocore by 4.8% during the 4th quarter. Fred Alger Management LLC now owns 8,359 shares of the company's stock valued at $477,000 after acquiring an additional 382 shares during the last quarter. Wells Fargo & Company MN boosted its holdings in shares of Immunocore by 89.7% during the 4th quarter. Wells Fargo & Company MN now owns 827 shares of the company's stock valued at $47,000 after acquiring an additional 391 shares during the last quarter. China Universal Asset Management Co. Ltd. boosted its holdings in shares of Immunocore by 103.9% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 836 shares of the company's stock valued at $43,000 after acquiring an additional 426 shares during the last quarter. IFP Advisors Inc boosted its holdings in shares of Immunocore by 32.9% during the 3rd quarter. IFP Advisors Inc now owns 2,397 shares of the company's stock valued at $124,000 after acquiring an additional 594 shares during the last quarter. Finally, Mariner LLC boosted its holdings in shares of Immunocore by 16.1% during the 3rd quarter. Mariner LLC now owns 4,331 shares of the company's stock valued at $225,000 after acquiring an additional 599 shares during the last quarter. Hedge funds and other institutional investors own 84.50% of the company's stock.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.